Spiegel, J., Alderuccio, J., Beitinjaneh, A., Wang, T., Holtzman, N., Pereira, D., Goodman, M., Jimenez, A. J., Benjamin, C., Alencar, A., Pongas, G., Lossos, I. S., Rosenblatt, J., Schatz, J., Stanchina, M., Trabolsi, A., Ramos, J. C., Moskowitz, C., Friedman, R., Paladugu, K., Menard, M., Green, D., Lekakis, L. (2025). Mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel induce high complete response rates at day+90 in Relapsed/Refractory large B-cell lymphoma. Blood. https://doi.org/10.1182/blood-2025-1009